Circadian Genes and Risk of Prostate Cancer in the Prostate Cancer Prevention Trial

Conclusions: We did not find strong evidence that circadian gene variants influenced prostate cancer risk in men who were not on finasteride treatment. There were suggestive associations between NPAS2 variants and prostate cancer risk among men using finasteride, which warrants further investigations. This article is protected by copyright. All rights reserved

Source: Molecular Carcinogenesis - January 10, 2018 Category: Molecular Biology Authors: Lisa W. Chu, Cathee Till, Baiyu Yang, Catherine M. Tangen, Phyllis J. Goodman, Kai Yu, Yong Zhu, Summer Han, Ashraful M. Hoque, Christine Ambrosone, Ian Thompson, Robin Leach, Ann W. Hsing Tags: BRIEF COMMUNICATION Source Type: research